Patents by Inventor Frederick Meins, Jr.

Frederick Meins, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA sequences encoding polypeptides having beta-1,3-glucanase activity
    Patent number: 6632981
    Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5′ region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: October 14, 2003
    Assignee: Novartis Finance Corporation
    Inventors: Frederick Meins, Jr., Hideaki Shinshi, Herman C. Wenzler, Jan Hofsteenge, John A. Ryals, Christoph Sperisen
  • DNA sequences encoding polypeptides having &bgr;-1,3-glucanase activity
    Patent number: 6262342
    Abstract: The present invention provides chemically regulatable DNA sequences capable of regulating transcription of an associated DNA sequence in plants or plant tissues, chimeric constructions containing such sequences, vectors containing such sequences and chimeric constructions, and transgenic plants and plant tissues containing these chimeric constructions. In one aspect, the chemically regulatable DNA sequences of the invention are derived from the 5′ region of genes encoding pathogenisis-related (PR) proteins. The present invention also provides anti-pathogenic sequences derived from novel cDNAs coding for PR proteins which can be genetically engineered and transformed into plants to confer enhanced resistance to disease.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: July 17, 2001
    Assignee: Novartis Finance Corporation
    Inventors: Frederick Meins, Jr., Hideaki Shinshi, Herman C. Wenzler, Jan Hofsteenge, John A. Ryals, Christoph Sperisen